Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Gastroenterology

Topics

Chemistry

Biochemistry

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1007/s00535-024-02185-w

License

CC-BY